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Abstract 
Aluminium salts are by far the most commonly used adjuvants in vaccines. There are only two aluminium salts 
which are used in clinically-approved vaccines,  Alhydrogel® and  AdjuPhos®, while the novel aluminium adjuvant 
used in  Gardasil® is a sulphated version of the latter. We have investigated the physicochemical properties of these 
two aluminium adjuvants and specifically in milieus approximating to both vaccine vehicles and the composition 
of injection sites. Additionally we have used a monocytic cell line to establish the relationship between their 
physicochemical properties and their internalisation and cytotoxicity. We emphasise that aluminium adjuvants used 
in clinically approved vaccines are chemically and biologically dissimilar with concomitantly potentially distinct roles 
in vaccine-related adverse events.
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Review
There are two aluminium based adjuvants (ABAs) 
commonly used in vaccines [1].  Alhydrogel® is a semi-
crystalline form of aluminium oxyhydroxide (AH) 
and  AdjuPhos® is an amorphous salt of aluminium 
hydroxyphosphate (AP). A sulphate salt of the latter 
(AAHS) is also listed as being one component of an 
adjuvant system used in vaccinations against HPV [2]. 
 Alhydrogel® and  AdjuPhos® are commonly referred to 
as clinically-approved ABAs [3] and yet this is not the 
case. There are no ABAs which have been approved for 
intramuscular or subcutaneous injection into humans. 
There are no requirements for their approval, they are 
only ‘approved’ as part of vaccine preparations.
Aluminium-adjuvanted vaccines have a long history 
of clinical successes and a commensurately long history 
of vaccine-related adverse events [4]. Since there is no 
requirement to demonstrate the safety of ABAs one could 
quickly surmise that adverse events following vaccination 
are the direct or indirect effects of ABAs. This is almost 
certainly true as the phenotypes of most adverse events 
are unrelated to the disease being treated and are 
reproduced, at least in the short term, in ‘clinical approval 
trials’ where ABAs are the ill thought through placebos 
[5]. It is almost certainly the widespread use of ABAs 
and/or other aluminium-adjuvanted vaccines as placebos 
in vaccine safety trials that have guaranteed clinical 
approval of many vaccines. The numbers of individuals 
affected by an adverse event is largely determined by how 
widely a vaccine is administered (essentially a percentage 
of those inoculated) while the clinical manifestation and 
severity of an adverse event may be almost bespoke to 
the vaccine recipient. To better appreciate how ABAs 
are responsible for adverse events we must start with 
an understanding of their physicochemical properties 
within the physiological environment of the injection 
site. Indeed such information might also be a starting 
point for the design of novel and safer ABAs for future 
applications in vaccines.
The clinical significance of the physicochemical 
properties of ABAs begins prior to their combination 
with the antigen of interest. This is because the nature of 
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their interaction with antigen will be influenced by the 
surface they present for adsorption of antigen and such 
surfaces will depend upon the particle size profile of 
the adjuvant material as well as such aspects as surface 
functionality, e.g. hydroxyl or hydroxyphosphate, and 
the overall surface charge in the vehicle used to suspend 
them. The antigen, upon mixing, may then be strongly 
adsorbed to adjuvant surfaces or it may simply be 
occluded within aggregates of adjuvant. Since there will 
also be some dissolution of ABA at this point then there 
may also be direct interactions, such as ionic binding, 
between antigen and Al3+(aq) . Even before its injection a 
vaccine preparation can be extremely heterogeneous 
in respect of the presentation of the adjuvant-antigen 
complex. The same preparation is then subject to its 
passage through a hypodermic needle and into the even 
more diverse environment of the injection site, whether it 
is intramuscular or sub-cutaneous.
One aspect of the injection of a vaccine that invariably 
seems to be ignored is the immediate acuity of such 
an exposure to aluminium. The concentration of total 
aluminium in the vaccine can be as much as 63  mM 
(1.7  mg/mL)  and immediately upon its dilution into 
interstitial fluid its concentration in the immediate 
vicinity of the injection site will remain high, mM, for 
minutes if not hours following the injection. The solubility 
of the ABA will increase markedly upon its dilution at the 
injection site, both due to dilution but also the influence 
of myriad solubilising moieties reacting with Al3+(aq) , and 
commensurate with this will be a significant increase 
in the biological availability of aluminium [6]. Toxicity 
will be inevitable under such conditions and might be 
expected to be manifested as necrotic cell death and a 
subsequent inflammatory response. Herein, perhaps, is 
the origin of the potent adjuvant activity of aluminium 
salts; an immediate potency (often manifested as a 
simple reddening and swelling of the skin at the site of 
the injection) which will depend upon the presentation 
of the aluminium salt in question and, critically, the 
physiological response of the recipient.
While some degree of toxicity and cell death is probably 
inevitable, all subsequent responses to the adjuvant will 
bear the signature of an individual and these iatrogenic 
effects can range from benign to fatal. In every case, we 
might expect some degree of innate immune response 
to the antigen and that this will involve harvesting of 
adjuvant/antigen complexes by infiltrating immune-
responsive phagocytic cell types. We know that ABAs 
are  taken up by monocytic T helper 1 (THP-1) [7] cells 
and we also know that these cells respond differently 
to different ABAs. What we do not know is how such 
different responses are manifested in the innate response. 
For example, is endocytosis of ABA a prerequisite 
for the successful generation of innate immunity to 
the associated antigen? The apparent capability for 
monocytes to endocytose significant amounts of ABA 
without suffering obvious toxicity adds the additional 
dimension of these cells being vehicles for the trafficking 
of aluminium adjuvant throughout the body and into the 
brain [8].
Different ABAs are neither physically nor chemically 
equivalent and importantly ABAs are significantly 
dissimilar to other non-ABAs such as silica or uric acid. 
It is a mistake to make the assumption that adjuvants 
share an exact or similar action. It is, therefore, similarly 
mistaken to assume that all adjuvants are capable of 
adverse events following vaccinations.
The physicochemical properties of ABAs and their 
respective contributions to the immunological 
potency of vaccines
The physicochemical characterisation of ABAs remained 
in its infancy until 1990, when many studies appeared 
on the subject in an attempt to address immunological 
issues resulting from inconsistent batch production. 
Indeed, the lack of industrial standardisation and 
optimisation involved in vaccine formulation was widely 
regarded as the reason behind the fluctuating efficacy 
of preparations containing identical base components. 
The culmination of these efforts was the identification 
of several physicochemical properties that influenced 
the adjuvanticity of aluminium salts, namely hydrated 
colloidal structure, particle size and surface charge [1]. 
While some attempt has been made to investigate the 
correlation between adjuvant physicochemistry and 
immunopotentiation (see [9, 10] for past reviews on the 
subject), the nuances of this relationship remain relatively 
enigmatic. This section will explore the correlation 
between these two parameters based on an evaluation 
of current literature and ultimately identify which 
fundamental issues remain to be addressed.
The structural characteristics of ABAs and their role 
in the immunological response towards ABAs
Aluminium hydroxide gels
The aluminium hydroxide salts used in vaccines are 
more structurally complex than inferred by their generic 
chemical designation. The structure of contemporary 
aluminium hydroxide adjuvants resembles that of 
boehmite (AH) rather than that of the polymorphic 
hydroxide gels synthesised in 1958 [11].  Alhydrogel®, 
for example, has infrared (IR) stretching and bending 
vibrations located in almost identical positions to those 
obtained specifically for AH, which include a strong 
hydroxyl deformation band and stretching shoulder 
around 1070 and 3100 cm−1 respectively [12]. However, 
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as noted by Wang et  al. the additional hydroxyl 
deformation peaks at 835, 890 and 965 cm−1 imply that 
the structure of these adjuvants is significantly more 
hydrated than that of well-ordered boehmites [13], an 
observation which may be attributed to the specific 
conditions under which they are synthesised. Utilising 
lower temperatures and more acidic conditions during 
the synthesis of boehmites encourages the formation 
of small crystallites containing an abundance of non-
stoichiometric water molecules, which are present 
both at the surface interface and intercalated between 
octahedral layers [14, 15]. The resulting crystallites 
are fibrillar in morphology expressing preferential 
elongation in the direction of the c axis and are in the 
region of 4.5  nm × 2.2  nm × 10  nm in size [13, 16–18], 
which is diminutive when compared to the larger plate 
like structures observed for highly crystalline boehmites 
[14]. These structures are thus characteristically more 
disordered and produce characteristic Bragg reflections 
which are broad in nature and diminished in intensity 
[14]. As a consequence, these poorly crystalline 
boehmites (PCB) have a substantially larger surface area 
than that of highly crystalline aluminium hydroxides 
such as I-gibbsite (510  m2/g [18] vs. 29  m2/g [19]). It is 
should be noted, however, that the value of the former 
is significantly reduced during the process of vaccine 
formulation. Immersion within physiological saline 
(0.15 M NaCl), for example, prompted a decrease in the 
specific surface area of two commercial AH adjuvants 
 (Alhydrogel® and  Rehydragel®) from 350 and 300 m2/g to 
225 and 150 m2/g respectively [20].
From a vaccinological perspective, the larger relative 
surface area of PCB gels appears to offer significant 
advantages in terms of antigenic adsorption over more 
crystalline analogues or those composed primarily 
of highly ordered polymorphic hydroxides. The AH 
adjuvants used in clinical vaccines, for instance, are 
touted as having high adsorptive capacities for myriad 
proteins under isotonic conditions. Notable examples 
include the adsorptive capacity of  Alhydrogel® for 
bovine serum albumin (BSA), β-casein and hepatitis B 
surface antigen (HBsAg) in 0.15 M NaCl, all of which are 
substantial at 1.25, 3.43 and 1.43 mg/mg Al respectively 
[21]. Despite these considerable values, the quantity 
of adjuvant used within prophylactic vaccines often 
greatly exceeds that of the antigen and thus ensures that 
complete adsorption is consistently achieved. These 
events induce conformational changes in the structure 
of the bound antigen, which theoretically increases 
both their proteolytic susceptibility and subsequent 
presentation to T cells via MHC class II molecules [22]. 
Furthermore, maximal antigen adsorption is reportedly 
necessary for the efficacy of immunisations containing 
S. pneumoniae amongst others [23]. The relationship 
between adsorptive capacity and immunopotentiation, 
however, remains equivocal and facilitating a higher 
percentage of antigenic adsorption within the 
vaccine preparation itself does not guarantee that the 
formulation will exhibit superior immunogenicity 
(see [24] for an extensive review of this subject). It is 
thus reasonable to conclude that the dependence of 
vaccine potency on adjuvant-antigen interaction is 
component specific and as such should be evaluated on 
an individual formulation basis.
The structural order of AH is also an important 
consideration in terms of tailoring their specific adjuvant 
activity when administered as part of a vaccine. Synthetic 
boehmite nanorods of lower structural order have been 
shown to stimulate the production of significantly 
elevated levels of IL-1β and IL-6 in  vivo in comparison 
to their more crystalline counterparts [25]. The presence 
of these pro-inflammatory cytokines is indicative of 
the classical Th2 polarisation typically associated with 
aluminium-adjuvanted vaccines [26–31]. Despite these 
initial results, the IgG1 titres potentiated by nanorod 
analogues were visually comparable 2  weeks following 
immunisation (fibrous vs. crystalline rod—ca 1 ± 0.4 and 
0.6 ± 0.4 ng/mL respectively), although it should be noted 
that statistical comparisons between candidates were not 
explicitly made or referred to within the text. Conversely, 
however, studies using more amorphous nanorods 
demonstrated that the level of IgG1 potentiated by these 
materials was significantly greater than those elicited by 
 Alhydrogel® 61 days post vaccination [29]. Nevertheless, 
this apparent disconnect between the initial innate 
and adaptive immunological responses noted in the 
former is consistent with the well-established belief that 
IL-6, in particular, has little to no influence upon the 
enhancement of adjuvant-associated immunoglobulin 
levels in  vivo [30]. Similarly, more recent research has 
demonstrated that while IL-1β appeared to promote 
the recruitment of leukocytes towards the injection 
site [31], its abolition also had a negligible impact upon 
the generation of murine OVA specific IgG [32–36]. 
While many studies, including this one [25], argue that 
the adjuvanticity of aluminium salts is mediated by the 
formation of the inflammasome complex [37, 38], there 
is now mounting evidence to suggest that the magnitude 
of antibody titres generated at early junctures post 
vaccination may be somewhat independent of these 
innate signalling pathways and structural crystallinity. 
Furthermore, morphological differences in the structure 
of these adjuvants may be more relevant in this context 
as rod-like candidates generated higher overall antibody 
titres than platy or polyhedron type structures.
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Allergic IgE responses were also diminished in mice 
vaccinated with more crystalline derivatives [25]. The 
reduction in IgE levels as a consequence of a departure 
from the application of more fibrous morphologies 
could theoretically be attributed to a reduction in IL-18 
production, another well documented component of the 
PCB cytokine milieu [39]. This cytokine, in conjunction 
with other members of the IL-1 superfamily, can also 
drive Th17 differentiation [40], an immunological 
pathway activated in mice immunised with adjuvanted 
vaccines containing intermediate to high doses of 
whole-cell bacterial antigens [41]. Furthermore, IL-18 
has been shown to positively influence the production 
of both mature and precursor forms of IL-1β [42], 
which is consistent with the attenuation of the latter in 
mice challenged with materials of higher crystallinity. 
It is thus evident that the solid-state chemistry of AH 
adjuvants may play a more significant role with regards 
to the regulation of immunoglobulin class switching. 
Explicit modulation of IgE responses via this route 
could be used to temper the increasing incidence of 
local hypersensitivity reactions in paediatric populations 
vaccinated with PCB containing vaccines (see 
communication by Bergfors et al. for a short summary of 
this topic [43]). If carefully conceived and implemented, 
it is feasible that such augmentations could improve the 
safety of such formulations without compromising their 
immunological efficacy.
Exposure to these nanorods also induced the secretion 
of significant levels of IL-12 from BDMCs after 8  h, 
which putatively suggests some degree of preferential 
polarisation towards a cell-mediated response [25]. It is 
thus tempting to speculate that the presence of IL-12 may 
drive some degree of IFN-γ dependent Th1 activation 
in this case. Though relatively uncommon, incidences 
of such phenomena have been observed following the 
administration of prophylactic formulations adjuvanted 
with commercial equivalents [44–47]. Indeed, novel 
proteomic approaches have highlighted a significant 
role for IFN-γ signalling pathways in the immunological 
mechanisms potentiated by AH, which specifically 
included increased expression of HLA molecules (class 
I and II) and the generation of  CD8+ memory cells 
[48]. The ability of PCB containing vaccines to enhance 
the generation of the latter is considered of particular 
importance in relation to the acquisition of sustained 
immunity towards pathogenic challenge [46]. Aluminium 
salts are, however, notoriously inept at inducing the 
terminal differentiation required to promote robust cell-
mediated responses [34, 46, 49]. In conjunction, this 
behaviour implies that sustained IL-12 production does 
not feature prominently in the immunological response 
towards commercial adjuvants [50]. In fact, others have 
demonstrated that formulations containing  Alhydrogel® 
actively inhibited APC derived IL-12 in a predominantly 
dose-dependent manner both alone and in the presence 
of a CpG oligonucleotide antigen [51]. The discrepancies 
between the IL-12 responses generated in reaction to 
synthetic vs. commercial boehmites in this case may 
lie in the different sampling durations chosen by each 
group (8 vs. 24  h). Additionally, while IL-12 signalling 
is indeed crucial with regards to the activation of Th1 
driven responses [52], it is also capable of evoking B cell-
mediated humoral immunity independently of IFN-γ 
by acting as an initial primer for the production of IL-6 
and IL-10, thereby inhibiting and self-regulating its 
own biological activity [53–55]. It is possible, therefore, 
that early IL-12 production by dendritic cells (DCs) 
in response to vaccines adjuvanted with AH may be 
indirectly responsible for directing murine immune 
responses towards a Th2 profile.
As a final remark regarding the study by Sun et  al. 
[25], the authors also purport to identify several 
analogues that out-performed a “commercial” adjuvant 
competitor  Imject® alum. It is worth noting however, 
that  Imject® alum was a poor comparative choice in 
this case as it is neither used in clinical vaccines nor is 
it an AH adjuvant [56]. In fact, this suspension is known 
for its poor immunogenicity in comparison to clinically 
utilized AH gels [57] and its use in experiments designed 
to investigate the mechanisms surrounding ABA 
immunopotentiation has been openly criticised [10, 56]. 
The clinical relevance of these findings are therefore 
difficult to assess and emphasises that the choice of 
commercial materials in such experiments should be 
carefully considered in order for meaningful comparisons 
to be made.
Aluminium phosphate
Aluminium phosphate suspensions and their 
sulphated derivatives represent a secondary choice 
of adjuvant for inclusion within vaccines that require 
an inorganic immunopotentiator. When analysed via 
IR spectroscopy, commercial preparations exhibit 
functional characteristics synonymous with that of 
AP, including a strong phosphate peak at ca 1100  cm−1 
and broad hydroxyl stretches in the range of ca 3500–
3100  cm−1 [12]. These adjuvants lack translational 
periodicity by X-ray diffraction (XRD) [12] and due 
to their amorphous nature contain a high proportion 
of adsorbed water molecules at the surface interface 
(unpublished observations). By transmission electron 
microscopy (TEM), AP demonstrates an aggregated platy 
morphology composed of nanoparticles approximately 
50  nm in size [12, 58]. Augmentations of synthetic 
conditions during the manufacture of this adjuvant 
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have been shown to induce a shift in the ratio of surface 
hydroxyl: phosphate groups exhibited by individual 
batches [59]. The extent of molecular phosphate inclusion 
is particularly important as it influences the surface 
properties of adjuvant particulates and the resultant 
efficacy of immunological potentiation [60–63].
Given the information presented in the previous 
sections, one could reasonably predict that the 
amorphous nature of AP adjuvants could facilitate: (i) 
the increased reactivity of the adjuvant at the injection 
site and (ii) higher levels of serum IgE production. The 
former has been demonstrated to some degree using 
comparative studies in which AP was determined to be 
more cytotoxic than AH in vitro [64]. The latter is more 
difficult to justify as few studies directly compare allergic 
responses potentiated by AP and AH adjuvants or indeed 
crystalline vs. amorphous AP preparations. Nevertheless, 
the administration of AP adsorbed vaccines does appear 
to elicit both protracted and significant levels of IgE 
secretion in rodents [65]. However, IL-4 is an essential 
requirement for the induction of allergic response 
towards aluminium salts [28] and there is currently 
no evidence to suggest that IL-4 production is more 
pronounced when vaccines adjuvanted with AP are 
administered [44]. Furthermore, if another indicator 
is used, namely IL-18, the response of human PBMCs 
to AP was substantially reduced in comparison to that 
potentiated by AH [39].
The recent development of AAHS by Merck has 
prompted its preferential inclusion and consequent 
displacement of AP in many of its vaccine formulations. 
Characterisation of this adjuvant still remains in its 
preliminary stages and literature sources pertaining 
to such are increasingly uncommon. In lieu of XRD 
analysis, AAHS has been described as an amorphous 
mesh with a perhaps unsurprising morphological 
resemblance to AP [66, 67]. Due to the lack of afore-
mentioned physicochemical studies, it is difficult to make 
objective comments upon the efficacy and safety of this 
preparation in relation to its structural characteristics. 
Furthermore, the only available comparative study 
demonstrated that while AAHS adjuvants elicited 
high levels of HPV specific IgG1 antibodies in mice 
immunized via the intramuscular route, these responses 
were not statistically different from those potentiated by 
AP [66]. Given the results of this study, the rationale for 
the use of AAHS over more traditional AP preparations 
is currently difficult to discern.
The role of particle size in the immunological response 
towards ABAs
The substantial efficacy of particulate delivery systems 
with respect to both immunopotentiation and 
immunomodulation post vaccination is universally 
accepted [68]. Homogenous sub-micron or nano-
particulate suspensions appear preferential with 
emphasis upon the use of the latter, a logic perpetuated 
by the inverse nature of the relationship between particle 
size and membrane permeability or cellular uptake [69]. 
The application of such a conclusion to the relative 
adjuvanticity of such populations in biological systems, 
however, is by no means unanimous.
The heterogeneity and aggregation capacity of ABAs 
in hydrodynamic systems, including those of the vaccine 
preparation and inoculation site, are persistent obstacles 
that hinder the investigation of the relationship between 
the relative size of these salts and the subsequent 
magnitude and pathway of immunopotentiation 
elicited in  vivo. Many have relied upon the use of 
stable, monodisperse particulate models such as 
polylactide (PLA) in order to elucidate the importance 
of this association [70–72]. However, application of these 
trends to ABAs is spurious at best given the numerous 
physicochemical differences observed between these 
preparations and those containing aluminium.
Other approaches have sought to compare the 
immunological response to both micron and nano-
sized aluminium particulates in order to minimise the 
variations in physicochemistry typically encountered 
when comparing ABAs. Perhaps unsurprisingly, AH 
nanoparticles and nanosticks out-performed their 
microparticle counterparts not only with regards to 
antibody generation but also induced a marked reduction 
in inflammation in  situ [29, 73]. Contrary to numerous 
reports [7, 8, 64, 74–76], both reported virtually no 
cellular uptake of OVA-conjoined microparticles 
relative to the rapid internalisation of nanoparticles, 
an argument presented as a major contributor to their 
increased adjuvanticity along with that of enhanced 
protein adsorption. However, the increased cytotoxicity 
of such materials as evidenced by their ability to induce 
significant levels of uric acid production in vivo provides 
a more convincing explanation [77]. AH nanoparticles 
have also been able to potentiate potent  CD8+ T cell 
responses, which makes them attractive potential 
candidates for vaccines against Tuberculosis [78] and 
those intended for immunotherapy [79]. While these 
studies are highly informative with regards to the 
development of more efficacious vaccine adjuvants, the 
application of their results with regards to elucidating 
the immunological mechanisms activated by clinically 
utilised ABAs is questionable. Moreover, the data 
presented in these studies challenges the well-established 
consensus that uptake of ABAs is a prerequisite for their 
immunological action, an increasingly improbable notion 
given the results of a recent study where aluminium 
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adjuvanted vaccines were administered intramuscularly 
to rhesus macaques [80].
The particle size of ABA stock suspensions
Early characterisation of native ABA preparations by 
TEM identified that although composed of heterogeneous 
microparticles [81] the average size of both suspensions 
was < 10 µm [82]. Indeed, under conditions that promote 
maximum aggregation i.e. the point of zero charge (PZC), 
the average size of synthetic AP candidates peaked at 
ca 3  µm [58]. These attempts to ascertain the particle 
size distribution (PSD) of ABAs were nevertheless 
problematic and utilised methodology where analysis was 
conducted in an anhydrous environment. The removal of 
water at crystallite interfaces has been shown to facilitate 
the nucleation and subsequent growth of particulates and 
adjuvant-diluent interactions are a crucial mediator of 
systemic agglomeration in colloidal suspensions [83–88].
Hydrodynamic analyses of ABA suspensions also have 
their limitations mainly due to the polydispersity of the 
preparations themselves; however, such methodologies 
provide an informative reference PSD under relevant 
environmental conditions. Our group recently reported 
that the median particle size of  Alhydrogel® and Adju-
Phos® by dynamic light scattering (DLS) was ca 3 and 
7 μm respectively [89]. The latter was in good agreement 
with that obtained by Kolade et al. using low angle laser 
light scattering for an equivalent commercial preparation 
(ca 6 μm) [90]. Others have used liquid particle counting 
techniques in order to demonstrate the diversity of 
micron sized agglomerates present within synthetic APs, 
which reportedly range from ca 2–100 μm [91]. Despite 
the smaller size values and monomodal distribution 
obtained via DLS, the high polydispersity of  Alhydrogel® 
solutions implied that several populations exceeded 
the maximum size limit of DLS. This was consistent 
with reports that described the PSD of this adjuvant 
as multimodal, with the contribution of additional 
peaks being recorded at ca 22 and 44  μm [92]. These 
results imply that the hydrodynamic size of ABAs is 
intricately complex. Furthermore, these hydrodynamic 
studies highlight that the elevated size of these colloidal 
suspensions may bear a distinct relation to their 
relative ability to form interactions with the aqueous 
environment through interfacial hydroxyl groups.
The particle size of ABAs within vaccine preparations
Adjuvanted vaccine formulations containing 
attenuated/inactivated pathogenic antigen associated 
with ABAs are usually administered in an isotonic 
solution of physiological saline. The matrix of this 
diluent is teaming with monovalent electrolytes which 
facilitate an increase in ionic strength relative to the 
minimalist environment of the native preparation.
When introduced into physiological saline, ABAs 
undergo extensive aggregation in comparison to 
that observed within ultrapure water (UPW) at 
equivalent concentrations of Al; however, a marked 
disaggregation is generally observed relative to that 
of the native stock [89]. The former can be attributed 
to a phenomenon known as charge screening, which 
actively reduces the repulsion between particulates 
[93]. The formation of smaller agglomerates in this 
case can be considered beneficial in terms of antigenic 
adsorption as preparations containing a higher 
proportion of larger entities typically exhibit lower 
proteinaceous absorption capacities [94]. Facilitating 
such events has been shown to increase the size of the 
resultant antigen-adjuvant complex [75, 89], which is 
likely to influence their subsequent recognition and 
uptake at the site of injection. Particulate coagulation 
has been traditionally considered to negatively impact 
the immunogenicity of immunisations in vivo; however, 
this remains largely dependent upon the extent of these 
events as preparations containing a smaller proportion 
of large agglomerates (> 10  μm) have been shown to 
be equally effective at potentiating humoral responses 
[83–87].
The influence of phosphate ions upon the PSD of 
ABAs has yet to be fully explored. Preliminary studies 
have suggested that at an equivalent concentration 
of Al, the particle size of  Alhydrogel® was reduced 
when formulated in PBS [95] relative to physiological 
saline [89]. Others have also postulated that antigenic 
adsorption onto AH in the presence of phosphate 
results in the formation of more compact particles, 
which in turn improves the efficacy of the vaccine [96]. 
Given the high adsorptive capacity of hydroxylated 
aluminium for inorganic phosphate, this first result is 
slightly perplexing. For example, Tang et  al. proposed 
that while ionic exchange was the predominant means 
by which phosphate was adsorbed by highly crystalline 
boehmites, an additional mechanism was observed 
with regards to more amorphous derivatives, which 
involved the precipitation of aluminium phosphate 
[97]. Lookman et  al. also supported this hypothesis, 
demonstrating that the precipitation of aluminium 
phosphate was restricted to the surface of aluminium 
hydroxide in systems exposed to high concentrations of 
phosphate [98]. Aluminium phosphate itself has been 
identified as an efficient chemical binding agent [99] 
and it is therefore more likely that its presence within 
these suspensions may serve as a nexus for particulate 
agglomeration in the absence of competing antigens.
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The particle size of ABAs at the site of intramuscular injection 
post administration
The extracellular milieu found at the site of intramuscular 
injection is a diverse environment rich in anionic and 
proteinaceous ligands for aluminium. Some examples 
include phosphate [100], citrate [101] and serum 
components [100]. In  situations where the association 
between antigen and adjuvant are limited, the former 
have been reported to contribute to significant levels 
of antigenic elution in  vitro [102–104]. Such a scenario 
yields particulates whose surfaces are almost devoid of 
antigenic material providing a suitable site for protein 
adsorption in  situ. This results in the formation of a 
hard corona whose speciation and magnitude shapes the 
biological identity and size of ABAs. Interstitial proteins 
are also known to compete for ABAs facilitating the 
displacement of antigen and subsequent evolution in 
protein corona composition [105].
The solubility of aluminium salts in biological fluid is 
largely dependent upon their individual physicochemical 
properties and is likely to be partially stymied due to 
the protective influence of this proteinaceous corona. 
However, smaller entities available for independent 
migration away from the injection site may, theoretically, 
still exist. It is reasonable to assume, therefore, that 
in response to injection related trauma, the increase 
in interstitial pressure will facilitate the rapid and 
independent removal of these species through the 
lymphatics [106], resulting in their presence within the 
draining lymph nodes [8] and bloodstream [107, 108] 
prior to leukocytic recruitment [109]. Furthermore, 
the translocation of these species is likely to be more 
pronounced for AH than AP at earlier junctures due 
to the more rapid initial dissolution rate of the former 
in  vivo [107, 108]. It is therefore not unreasonable 
to suggest that the independent migration of such 
species may provide one of the initial stimuli for the 
immunological response potentiated by aluminium salts.
The remaining adjuvant material available at the 
injection site resides predominantly within the micron 
range and represents the greatest deposit of extracellular 
aluminium whose clearance and translocation will be 
dependent upon ingestion by APCs [110]. While the 
kinetics of internalisation will be different with regards 
to the dynamic environment found in vivo [109], uptake 
of particles by APCs is likely to occur relatively quickly 
after administration. The size of particles encountered 
within this timeframe will likely induce a predominantly 
phagocytic mechanism of uptake, although there will 
still be some discrete populations available for receptor-
mediated endocytosis [111]. Materials composed 
of smaller particles are more avidly internalised by 
APCs [64, 70, 75, 112]. However, the requirement of 
ABA phagocytosis in order to potentiate an immune 
response has been questioned by several reports, 
which demonstrated an absence of material within the 
intracellular compartment of APCs despite the generation 
of robust adaptive immunity [29, 73, 113]. Such events 
appear counter-intuitive considering the essential role 
of phagocytosis in the destruction and direction of the 
immune response against pathogenic bacteria [114], the 
majority of which have sizes residing in the region of 
1–4  μm [115]. In addition, cells of a monocytic lineage 
typically exhibit a highly conserved ruffled membrane 
[116], which has been implicated in the preferential 
uptake of particles whose sizes correspond to this range, 
although the attachment and subsequent internalisation 
of 2–3  μm structures is considered optimal [117]. 
Furthermore, the variation in abundance of particles 
existing below ca 3  μm provides a novel explanation 
concerning the relationship between particle size and the 
magnitude of adjuvant uptake by phagocytes observed 
in  vitro. The application of this theory to ABAs reveals 
that materials containing a greater abundance of these 
particles upon exposure to biological medium are more 
readily endocytosed than their larger counterparts and 
are also able to target more of the surrounding cellular 
population (AH > AP) [64]. Larger particles were also 
observed within the intracellular environment of THP-1 
cells, although the number of these entities was severely 
restricted. Such trends emphasise the importance of size 
with regards to the operation of the phagocytic pathway, 
which is often hindered by larger particles due to the 
relationship between the kinetics of cell signalling and 
manifestation of inhibitory signals [118]. Nevertheless, 
larger particles often have greater amounts of aluminium 
associated with their structure and the internalisation 
of a few of these entities may result in the delivery of a 
greater concentration of aluminium into the intracellular 
compartment of phagocytic cells. This may provide 
an initial justification for the observation that larger 
aluminium adjuvant particles promote greater levels of 
cytotoxicity in vitro [64].
The role of zeta potential in the immunological response 
towards ABAs
There are a plethora of mechanisms by which antigens 
typically associate with the surface of ABAs. ABAs 
exhibit distinct differences in PZC permitting the 
adsorption of a specific spectrum of pathogenic and 
allergenic proteins at ca pH 7.4, which is equivalent to 
that experienced within the vaccine preparation and 
at the injection site [119, 120]. For example, AH, which 
is positively charged at physiological pH, will form 
electrostatic associations with negatively charged species 
such as BSA thereby facilitating surface adsorption. By 
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contrast, AP, which is negatively charged within the 
afore-mentioned pH range, exhibits a higher affinity for 
positively charged antigens such as lysozyme. Although 
this model is well established, further studies revealed 
that while attractive forces including electrostatic 
interactions, hydrogen bonding, hydrophobic and van der 
Waal forces contributed to the absorption of proteins by 
aluminium salts, adsorption was not guaranteed in these 
systems if repulsive forces predominated in  situ [121]. 
The recent immobilisation of AH upon a quartz crystal 
microbalance sensor also revealed that the adsorption of 
BSA by this material could not be adequately explained 
by electrostatic mechanisms alone [122]. In conjunction, 
these studies suggest that antigenic adsorption within 
vaccine preparations may occur through additional 
mechanisms and be more complex than originally 
contemplated.
Vaccine subunits exhibiting bipolar tendencies can 
also interact with both ABA compounds, although the 
orientation of antigen domain is inevitably dependent 
on the relative charges involved [123]. While variance 
in protein orientation appears to be redundant with 
regards to immunopotentiation in this case, structural 
degradation and unfolding [22, 124], expedited by the 
individual micro-environmental pH at the adjuvant 
surface [125], can promote enhanced antigen-adjuvant 
interaction [102, 126] followed by a concomitant 
decrease in antibody production [127]. However, this 
trend is not universally upheld for all such adjuvant-
antigen complexes [128]. Phosphorylated antigens also 
target and preferentially bind hydroxylated surfaces 
through ligand exchange creating complexes with high 
associative strength [129].
The degree of antigenic adsorption to particulate 
entities is regarded as a crucial factor governing 
the potentiation of the immune response towards 
aluminium-adjuvanted vaccinations [130], facilitating 
T cell responses through improved cross presentation 
via enhanced cellular uptake [75, 131]. Indeed, when 
administered subcutaneously the elution rate of 
antigens adsorbed by electrostatic mechanisms was 
greater than those held by ligand exchange, consistent 
with the enhanced retention of the latter at the site of 
inoculation [60, 132]. While antigenic retention may be 
considered beneficial with regards to interaction with 
infiltrating inflammatory monocytic populations, these 
studies were the first to highlight that the strength of 
antigenic adsorption is in fact inversely proportional to 
the antibody response mounted in  vivo. Preparations 
with the largest degree of phosphate modification have 
typically exhibited the lowest adsorptive affinities [60, 
61, 94, 132] and thus potentiated the most substantial 
immune response in animal models [60, 61, 132]. Hence, 
phosphate treatment of AH has been successfully 
employed to improve the efficacy of vaccine formulations 
in several studies [61–63]. Furthermore, robust antibody 
responses are mounted against vaccines in which 
minimal adsorptive forces are displayed between antigen 
and ABAs [133, 134]. Despite the predominance of 
repulsive interactions, the latter observed an association 
between the two components in which the antigenic 
species became entrapped within adjuvant void spaces. 
This permitted simultaneous internalisation of antigen 
and adjuvant by APCs and provided a novel mechanism 
of immunopotentiation independent of antigen 
adsorption to aluminium salts.
While the zeta potential of aluminium salts influences 
the magnitude of proteinaceous adsorption observed 
within biological media, no correlation between this 
parameter and particulate uptake has been definitively 
demonstrated. The instantaneous nature of the 
adsorption of interstitial proteins by these adjuvants 
often results in the transformation of their surfaces to 
reflect negative charges of equivalent magnitude [64], 
making comparisons of this nature virtually impossible. 
Others have also struggled to demonstrate a significant 
role for surface charge with regards to both the efficacy 
of AH nanorod endocytosis and resultant titres of OVA 
specific IgG1 and IgE [135]. Previous studies investigating 
the coronal composition of cationic, neutral and anionic 
particles have demonstrated that the latter are more 
effectively opsonised through the association of IgG with 
their surfaces [136]. Furthermore, opsonised particulates 
of equivalent sizes exhibited greater levels of phagocytic 
uptake than those lacking this motif, an event which was 
mediated through interaction with Fc receptors on the 
surface of macrophages [137].
Cellular uptake of aluminium adjuvants in human 
vaccinations
Advances in modern-day vaccine engineering have 
allowed for the production of highly purified protein 
antigens in large quantities that boast excellent safety 
profiles [138]. Unfortunately, immunisation using antigen 
only results in little to no antibody production. Therefore, 
it has remained necessary to include particulate 
substrates in vaccines to overcome this barrier [138, 
139]. It is the immunostimulatory properties of ABAs, 
described as their ‘adjuvanticity’ that has driven their 
predominant and continued use in human vaccinations 
[138]. Of the fundamental mechanisms governing 
the adjuvanticity of ABAs are their ability to provide 
enhanced delivery of antigens to APCs, subsequently 
initiating an immune response and high antibody 
titers (Fig. 1) [10, 138]. For this reason, when ABAs are 
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formulated in vaccines they are generally added in excess 
[138].
Some debate has ensued in the scientific literature 
as to the importance of the binding avidity of the ABA 
to the antigen in potentiating and shaping the resultant 
immune response [10, 60, 138]. If the antigen remains 
tightly adsorbed to its ABA as for studies using alpha-
casein and  Alhydrogel® respectively, then such high-
affinity interactions diminish the immunostimulatory 
properties of the vaccine [60]. As such, the choice of 
antigen in a vaccine dictates its ability to dissociate from 
its ABA [10], yet is often solely chosen dependent upon 
its charge. Weak electrostatic forces of attraction result in 
the rapid dissolution of the antigen in muscle interstitial 
fluid (MIF) at the injection site [10]. As such, it cannot 
be presumed that the entirety of ABA particulates remain 
co-adsorbed to their highly purified target antigen [6]. 
These effects have been described previously as the depot 
effect of ABAs, whereby the presence of aluminium in 
the vaccine prolongs the persistence of the antigen at 
the injection site [10, 139]. This theory has since been 
disputed as injection sites could be excised without 
affecting the adjuvanticity of the administered ABAs 
[140, 141].
Ligand and electrostatic interactions still give rise to 
antigen persistence at the injection site [109]. Therefore, 
two general modes of action for ABAs may be surmised 
in explaining their immunostimulatory effects in  vivo. 
Fig. 1 Biological processing of vaccines containing ABAs following intramuscular injection. 1. Vaccine preparation includes antigen adsorbed 
on the surface of the ABA, occluded within aggregates of ABA and, potentially, free antigen. 2. Biological fate of vaccine constituents includes; 
independent translocation of antigen (< ca 200 nm) to lymph nodes (2a); inflammatory monocyte/macrophage uptake of larger antigens through 
micropinocytosis (2c); intracellular antigens are either processed by the lysosomal system (L) or evade lysosomal capture through rupture of the 
endosome (2e); antigen associated with ABA (adsorbed or occluded) is internalised by phagocytosis (2b) and processed via autophagy, endosomes 
maturing into autophagosomes and ultimately, autolysosomes (AL) (2d). The biological mechanisms involved in the processing of these various 
entities contribute to the downstream activation of complexes such as the NALP-3 inflammasome and the subsequent release of pro-inflammatory 
cytokines including IL-1β
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Firstly, increased antigen persistence by ABAs allows for 
sufficient recruitment and accumulation of infiltrating 
inflammatory cells to initiate an immune response at 
the injection site [10, 109]. Secondly, the subsequent 
association of the ABA to the antigen promotes their 
interaction and potential cellular uptake by infiltrating 
APCs, further driving the initiation of an immune 
response [109]. Thus, ABAs are able to potentiate the 
immune response whether co-adsorbed or dissociated 
from their target antigen in a vaccine.
Cellular mechanisms of aluminium adjuvant uptake
The scientific literature to date has almost entirely 
focused upon the cellular uptake of the antigen in a 
vaccine formulation. Consequently, the question remains 
as to how the cellular uptake of ABAs and their transport 
to locations distant from the injection site contributes to 
this process [6, 10, 60, 109, 139]. In drawing comparisons 
between the cellular uptake of the two ABAs used most 
frequently in clinical vaccinations,  Alhydrogel® and 
Adju-Phos®, consideration must be given to the cellular 
routes of uptake of ABAs and the types of cells recruited 
to the site of injection. The process of cellular uptake is 
stringently controlled at the plasma membrane of the cell, 
which allows for both the passage of substances from the 
extracellular space into the cell cytosol via endocytosis 
and their expulsion from the intracellular space via 
exocytosis [142]. Therefore, the interchange between 
these two important cellular transport mechanisms will 
ultimately be responsible for driving the cellular passage 
of ABAs [142, 143].
Non‑specific endocytic mechanisms of cellular uptake
Non-specific mechanisms of endocytosis can be defined 
as cellular uptake mechanisms whereby internalisation 
is achieved without the use of specific receptors such as 
protein transporters embedded in the cell membrane 
[142]. Upon the administration of the vaccine formulation 
to the injection site, the degree of heterogeneity with 
regards to the ABA and antigen species formed, 
inevitably increases [6]. Therefore, administration of an 
ABA into the extracellular space would likely drive its 
dissociation into non-particulate forms [144]. Therefore, 
immunisation with an ABA would be expected to release 
the free solvated trivalent metal cation, Al3+(aq) , at the 
injection site [6]. As the principal bio-reactive species 
of aluminium, the release of Al3+(aq) into physiological 
milieu would have the potential in vivo for complexation, 
forming high and low molecular weight charged and 
neutral soluble species of the metal ion [144].
In addition, these ‘break-down’ products of ABAs may 
also be released into MIF once degraded intracellularly 
and exocytosed from cells and hence represent all 
forms of non-particulate ABA. Endocytic mechanisms 
are tightly-regulated by the size of the extracellular 
substance [142]. Therefore, all non-particulate forms 
of ABAs of a  size greater than a few nanometres would 
not be expected to diffuse through cellular pores of 
sub-nanometre dimensions, but rather cross cellular 
membranes by non-receptor mediated endocytosis [142–
144]. These cellular mechanisms of uptake may occur 
by simple diffusion known as transcellular transport, 
against an electrochemical gradient or require energy 
in the form of adenosine triphosphate (ATP) for uptake 
by active transport, cross ion channels or pores in the 
cell membrane or alternatively traverse the extracellular 
space through cell layers via paracellular transport [6, 
142].
Paracellular transport is achieved through selectively 
permeable barriers that consist of epithelial and 
endothelial cell layers such as those found in the blood–
brain barrier (BBB), forming tight junctions between 
adjoining cells [6]. In the presence of aluminium, 
residual leakiness of these membranes including the 
BBB has been noted, thereby diminishing the ability of 
tight junctions to restrict the passage of substances into 
the brain, promoting the free diffusion of aluminium 
between cells [144]. It remains unlikely however, that 
paracellular transport would allow for the free cellular 
passage of nano- or  micron-sized particulates of either 
 Alhydrogel® or Adju-Phos® due to the close proximity 
of even compromised cell layers [143]. Furthermore, as 
this cellular transport mechanism fails to result in the 
direct cellular uptake of at least particulate ABAs, other 
mechanisms of cellular internalisation would be expected 
to occur once particles interact with the cell membrane 
(Fig. 1) [142, 143].
Transcellular transport does not require specific 
receptors on the cell membrane, thereby acting as a 
diffusive process of cellular uptake. Since an unequivocal 
mechanism has yet to be elucidated for the transcellular 
transport of aluminium, combined with the expected 
blockade of this mechanism of cellular transport via 
the intracellular accumulation of Al3+(aq) , little evidence 
supports a significant role for this route of uptake [144]. 
Low molecular weight neutral complexes of aluminium 
would, however, accumulate over time in cells via their 
transcellular diffusion through the plasma membrane 
and via ion channels into cell cytosol. Charged low 
molecular weight complexes of aluminium are predicted 
to be internalised via active transport [144], driven 
through variances in charge between exoplasmic vesicle 
membranes and the cytosolic cell face [145]. Finally, 
high molecular weight complexes of aluminium carrying 
neutral charge would be likely internalised in vesicles via 
non-specific adsorptive endocytosis [143, 144].
Page 11 of 19Shardlow et al. Allergy Asthma Clin Immunol           (2018) 14:80 
The amorphous nature of Adju-Phos® as an AP based 
adjuvant would be expected to more readily dissociate 
to give Al3+(aq) , than semi-crystalline  Alhydrogel®, an AH 
based adjuvant. Therefore, while both ABAs would give 
rise to increased concentrations of the trivalent metal 
cation at the injection site, the more rapid dissociation 
of Adju-Phos® would be predicted to result in a greater 
proportion of high and low molecular weight soluble 
complexes of aluminium [144]. As such, immunisation 
using Adju-Phos® may result in the reduced loading of 
nanometre and micrometre-sized particulate aggregates 
versus  Alhydrogel®, thus lowering the adsorptive capacity 
of the ABA to protein antigens [6, 140]. Therefore, in 
the absence of unequivocal data concerning these latter 
mechanisms of cellular uptake, a role for the adsorptive 
capacity of ABAs upon the potentiation of the immune 
response remains to be elucidated.
Endocytic mechanisms governing the cellular uptake 
of particulate aluminium adjuvants
All pathways of endocytosis result in the cellular 
internalisation of ABA particles, ultimately resulting in 
their presence within lysosomal compartments in cell 
cytosol [144]. Specialist variations of endocytosis can 
be defined under six recognised pathways consisting 
of phagocytosis, macropinocytosis, clathrin-mediated 
endocytosis, caveolar-mediated endocytosis, pinocytosis 
and adsorptive or non-receptor mediated endocytosis 
[142, 143]. Phagocytosis is a form of endocytosis and a 
process of cellular uptake that relies upon mechanical 
interactions of phagocytic cells with apoptotic or 
necrotic cells, cellular fragments, pathogens or particles 
that fall in the approximate size range of 0.5–5  μm and 
is only possible by a limited number of cell types [109, 
117]. As an actin-regulated mechanism of engulfment, 
reorganisation of the actin cytoskeleton is necessary 
to allow for cellular uptake [144]. This mechanism of 
uptake can often be of detriment to the cell, however, 
due to the necessity of the formation of large pores in 
the cell membrane. As such, phagocytosed substances 
are engulfed through cup-shaped protrusions in the cell 
membrane that gradually approach and close around 
particulate matter [143].
Phagocytosis is one  of the most recognised cellular 
pathway governing the internalisation of micron or 
nano-sized particulates of ABAs and is controlled by 
the molecular process of autophagy [144, 146]. The 
entry of particulate material into the cell initiates the 
formation of the phagophore of shape and size dictated 
by the engulfed substance [143]. The recruitment of the 
cytosolic light chain protein 3 (LC3) to the phagophore, 
forms a double-membrane known as an autophagosome 
which is vesicular in nature and encompasses engulfed 
particulates as well as mitochondria and peroxisomes 
[147]. Peroxisomes are found in all eukaryotic cells 
and are small membrane-bound cytoplasmic cellular 
organelles that contain a host of enzymes including 
catalase and urate oxidase that participate in a variety of 
oxidative mechanisms [145].
In the latter stages of autophagy and most notably 
for macroautophagy [147], a lysosome combines with 
the autophagosome triggering its maturation into an 
autolysosome, following the dissociation of LC3 from 
the membrane. The lysosomal contents spill into the 
autolysosome releasing enzymes including cathepsin 
B which acidify the resultant vesicular compartments 
to approximately pH 4.0 [146]. This results in the 
degradation of internalised particulates of the ABA, 
thereby releasing Al3+(aq) into cell cytosol [6, 144, 146]. 
The release of cathepsin B has been suggested to act 
as an endogenous danger signal that in combination 
with degradative products of ABAs, triggers localised 
inflammation at the injection site [148].
Phagocytosis is the optimal mechanism of cellular 
uptake when particles are in the size range of 1–3  μm 
(Fig.  1) [117, 142]. Macropinocytosis as a phagocytic 
cellular uptake mechanism would likely govern the 
cellular uptake of particulate material ≤ 1  μm owing to 
their maximal outreaching pore size of a few hundred 
nanometres in the extracellular space [142]. As with 
phagocytosis, this cellular process of uptake only occurs 
in a limited number of phagocytic cells and requires 
the rearrangement of the actin cytoskeleton, though 
arguably to a lesser extent to allow for the cellular passage 
of smaller sub-micron-sized particles [142, 143]. In this 
process, a large volume of extracellular fluid containing 
particulate matter is engulfed via the ruffling of the 
cell membrane that gives rise to varying shapes of the 
vesicles upon closure. Large cellular organelles known as 
macropinosomes [143, 149] then form, which may also 
account for the internalisation of lower molecular weight 
species of aluminium [144].
Clathrin-mediated endocytosis engulfs particles 
through the formation of cytoplasmic clathrin-
coated pits that initiate a process of self-assembly into 
polygonal-shaped cages, facilitating cellular uptake [143]. 
This mechanism of uptake is more likely to play a role in 
the uptake of the free protein antigen in a vaccine [6], 
of which an adsorbed ABA would only be internalised 
if its size was less than that of clathrin-coated vesicles 
of approximately 100  nm [142, 143]. Caveolin-driven 
endocytosis results in the formation of caveolin protein-
coated cytoplasmic hairpin-like depressions, up to 80 nm 
in diameter. While both Clathrin and caveolin-endocytic 
cellular mechanisms of particulate uptake are able to 
occur through receptor-mediated and independent 
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mechanisms, their contributory role to the uptake of 
particulate ABAs is likely to be minimal. Finally, small 
sub-nanometre particles may enter the cell via simple 
diffusion across the cellular phospholipid membrane 
bilayer [143], as with lower molecular weight species of 
aluminium [144].
Intracellular tracing of protein antigens 
via fluorescent‑labelling methodologies
Owing to the difficulties encountered in controlling the 
particle size of amorphous preparations of aluminium 
adjuvants, polystyrene particles have previously been 
used to assess the effects of particle size upon their 
ability to potentiate the immune response. As with 
the use of nanometre-sized ABA particles, greater 
immunopotentiation was noted for particles of 230  nm 
versus larger particles, following their intradermal 
injection in mice [150]. As with previous studies of this 
nature, however, the method relied upon the adsorption 
of OVA to adjuvant particles. OVA is frequently used as 
an antigen in vaccine research to study the effects that 
ABA elicit upon the immune response [73, 150]. The 
predominant reason for the use of this so-called ‘model 
antigen’ is the ease in which it may be conjugated to 
the fluorescent tag fluorescein isothiocyanate (FITC), 
subsequently allowing for its cellular internalisation to 
be conferred via flow cytometry, fluorescence and or 
confocal microscopy [73].
Green fluorescent protein (GFP) has also been used to 
allow for the cellular uptake of labelled protein antigens 
to be determined [151]. As these large fluorescent 
molecules may dissociate from their adsorbed antigen 
in both in  vitro cell culture and in  vivo animal models, 
the identification of these probes within cells cannot 
be used to infer the intracellular presence of the ABA. 
While intrinsic fluorescence of the protein antigen only 
in the ultraviolet range of the electromagnetic spectrum 
has allowed for its concentration to be determined when 
associated to its ABA, labelling of the vaccine would 
likely be necessitated to allow for its intracellular tracing 
[152]. Building upon these approaches, new methods 
have been devised to unequivocally identify ABAs, 
allowing their cellular fate to be determined in cellular 
models of vaccination [7, 153].
Non‑phagocytic mechanisms of immunopotentiation 
for aluminium adjuvants
The Nalp3 (or NLRP3) inflammasome is an intracellular 
multi-protein complex containing a pattern recognition 
receptor (PRR) composed of leucine-rich repeats (LLRs) 
that belong to the nucleotide-binding oligomerisation 
domain (NOD)-like receptor family [37]. Upon assembly, 
this large intracellular protein machinery forms a 
complex with apoptosis-associated speck-like protein 
containing a caspase recruitment domain and caspase-1 
(ASC) [37]. The activation of the inflammasome by 
particulate and or crystalline ABAs has been shown to 
promote the secretion of mature IL-1β and IL-18 that are 
cleaved from the pro-interleukins by activated caspase-1 
that subsequently enhance the immune response [37]. 
Antibody production has however been noted, without 
activation of the Nalp3 inflammasome [154, 155].
A non-phagocytic pathway has been suggested for 
ABAs in their ability to enhance the delivery and cellular 
uptake of protein antigens by professional APCs, while 
evading cellular internalisation of the adjuvant [113]. 
Therein, the interaction of ABAs adsorbed to OVA 
protein antigens at the cell surface of activated DCs was 
found to trigger lipid sorting and in turn, the activated DC 
surface was found to initiate a non-phagocytic delivery 
mechanism of the antigen only [113]. Although such a 
process of abortive phagocytosis has been proposed for 
ABAs, in the same study the semi-quantitative analysis 
of DCs exposed to ABAs via transmission electron 
microscopy (TEM), occasionally revealed apparent 
electron-dense particulates internalised within the cell 
cytoplasm [113, 156]. Therefore, DCs are suggested to 
retain their phagocytosing capacity at the injection site 
and hence a role for the cellular uptake of ABAs upon 
the potentiation of an immune response cannot be 
overlooked. Furthermore, as crystalline ABAs have been 
suggested to act as damage-associated molecular patterns 
(DAMPs) and activators of the Nalp3 inflammasome, 
their cellular uptake may be contributory if not essential 
for the adjuvanticity of ABAs [37, 154].
A recognised cellular pathway of immunopotentiation 
by aluminium adjuvants
ABAs have been suggested to potentiate the immune 
response by providing an enhanced delivery mechanism 
of the co-adsorbed antigen to DCs [138]. ABAs are also 
thought to be able to increase the antigen uptake and 
antigen presentation on the cell surface of activated DCs 
via major histocompatibility complex class II molecules 
(MHCII) [151]. Therefore, the enhanced number of 
MHCII-presented antigen sites upon DCs are thought to 
be able to engage naïve  CD4+ T cells that upon binding 
differentiate, dependent on the cytokines released by 
DCs, initiated by the transcriptional nuclear factor-κB 
(NF-κB) entering the nucleus of the DC [113, 138]. The 
subsequent activation of the Nalp3 inflammasome by 
particulate ABAs via the activation of the SyK and PI3K 
pathway produces IL-18 and IL-1β that are released into 
the extracellular matrix along with the pro-inflammatory 
IL-17 cytokine (Fig.  1) [37, 113]. The differentiated T 
lymphocytes then activate B cells that in turn produce an 
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increased number of antibodies and predominantly that 
of IgG, thereby driving humoral-mediated immunity and 
a  TH2 response [10, 156].
Cell recruitment
ABAs have been found to recruit a host of innate 
immune cells to the injection site including neutrophils, 
eosinophils, immature DCs, monocytes, macrophages 
and natural killer cells [34, 109, 142, 143]. The effects 
that ABAs elicit upon the relative abundance of each 
aforementioned cell type, their migration from the 
injection site and their capacity to promote the cellular 
uptake and presentation of the antigen to adaptive 
immune cells, directly impacts upon their ability to 
potentiate the immune response [10, 37, 80, 109].
Immunofluorescence of excised injection sites from 
immunised mice using fluorescently-labelled antibodies 
has been used to identify infiltrating cell types [8]. It 
has been found that regardless of whether the ABA 
is administered via intraperitoneal or intramuscular 
injection [109, 142], neutrophils are found to dominate 
the injection site only a few hours following vaccination 
[34]. As a phagocytic cell line, the arrival of neutrophils 
at the injection site would likely result in the engulfment 
of  particulates in the size range of 0.5–5  μm [142], 
although phagocytosis of the ABAs would be more 
pronounced following the arrival of monocytes after 
24 h and the vast recruitment of macrophages following 
7 days [109].
A marked increase in the presence of eosinophils are 
typically observed at day 7 following immunisation, 
concomitant with increased numbers of infiltrating 
MHCII-positive (+) DCs at the injection site [35, 109]. 
In spite of their non-phagocytic nature, eosinophils 
have been found to be contributory to the promotion of 
humoral-mediated immunity and hence the production 
of antibodies in the presence of ABAs [109]. Monocytes 
are able to differentiate into both macrophagic and 
dendritic cell types and increased numbers of  MHCII+ 
DCs at the injection site at day 7, have been linked to 
their presence [34, 109]. Overall, the rapid infiltration 
of innate immune cells is thought to be critical for the 
initiation of an adaptive immune response and the 
production of antibodies of which  MHCII+ DCs have 
been found imperative for the adjuvanticity of ABAs and 
the activation of the Nalp3 inflammasome [37, 113, 156].
Research methods for the identification of intracellular 
aluminium adjuvants
Lumogallion [4-chloro-3-(2,4-dihydroxyphenylazo)-
2-hydroxybenzene-1-sulphonic acid] is a fluorescent 
stain for aluminium and has been used successfully for 
both the quantitative and qualitative determination 
of aluminium in natural waters [157] and biota [158], 
respectively. Lumogallion was originally used for the 
fluorimetric detection of aluminium in sea and river 
water owing to its extremely low limit of detection 
of 2  nM comparable to inductively coupled plasma 
mass spectroscopy (ICP-MS) [159]. The proposed 
1:1 coordination of aluminium to the fluorophore is 
suggested to occur via the two phenolic oxygen ions and 
the azo group binding to the metal ion, forming complex 
rings in aromatic linkages. In this manner, lumogallion 
has been proposed to act as a planar tridentate ligand for 
aluminium [159].
To date, the fluorescent stain morin 
[2′,3,4′,5,7-Pentahydroxyflavone] has remained the 
most frequently used fluorophore for the detection of 
aluminium in plant and animal tissues producing a green 
fluorescence emission at 420  nm, through coordinating 
3:1 with the metal ion [160]. Unlike morin, lumogallion 
produces no detectable fluorescence in the presence of 
divalent metal cations including physiologically relevant 
concentrations of calcium and magnesium [159, 161]. 
Furthermore, while lumogallion is known to bind to iron, 
this results in the formation of a non-fluorescent complex 
that upon excitation at 500  nm achieves no detectable 
fluorescence maxima at ca 590 nm (orange), unlike that 
observed in the presence of aluminium [161]. Therefore, 
lumogallion has high specificity and selectivity for the 
binding and detection of aluminium, respectively. Such 
properties have rendered the fluorophore invaluable for 
the unequivocal identification of aluminium in both cells 
[7, 65, 144, 153, 162, 163] and tissues [164–166].
With regards to ABAs, lumogallion has allowed for 
the unequivocal identification of AH-based adjuvant 
formulations, including  Alhydrogel® within monocytic 
THP-1 cells [7]. As an immunologically relevant 
cell line [64] monocytes are known to be one of the 
first phagocytosing cell lines recruited to the site of 
vaccination and hence act as a significant carrier or 
vehicle of particulate ABAs, away from the injection site 
[109]. Using fluorescence microscopy complemented 
with TEM, vesicle or endosome-like structures were 
identified in cell cytosol of approximately 0.5–1  μm 
in diameter [7]. While it might be expected for a 
phagocytosing cell line to internalise micron-sized 
adjuvant particles into lysosomal compartments, all 
such published data prior to this study provided little or 
equivocal data of such. Therefore, this study highlighted 
lumogallion as an excellent fluorescent molecular probe 
for the identification of particulate ABAs [7, 153].
The use of lumogallion as a sensitive fluorescent 
molecular probe for aluminium [7] has revealed the 
unequivocal identification of particulates of  Alhydrogel® 
and Adju-Phos® in vesicle-like structures in the 
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cytoplasm of a relevant monocytic THP-1 cell line [64]. 
For both adjuvant formulations those particulates 
internalised were of approximately 1 μm in size and were 
found exclusively in the cell cytoplasm. As  Alhydrogel® 
was found internalised at every concentration of the 
adjuvant, this demonstrated its greater cytoplasmic 
loading versus Adju-Phos® whereby uptake was 
diminished at 50 and 100  μg/mL of the ABA. As such, 
this may infer that AH based adjuvants are more prone 
to migrate from the injection site [64]. The release of 
extracellular DNA from dying cells has been found to 
enhance the adjuvanticity of ABAs, as DAMPs that 
activate the Nalp3 inflammasome [138, 167]. Therefore, 
the reduced cellular uptake of Adju-Phos® and its 
enhanced cytotoxicity at the injection site in comparison 
to  Alhydrogel® may act to mediate its adjuvanticity by an 
alternative cellular pathway of immunopotentiation [64].
Direct fluorescent labelling of vaccine antigens
Attempts to monitor the cellular uptake of antigens 
in vaccine formulations have frequently made use of 
commercially available fluorochromes or conjugated 
immunolabels for detection via fluorescence [168] 
and electron microscopy [169], respectively. While 
such labels are readily detectable under the respective 
imaging modalities [170], whether or not they remain 
co-localised to their target antigen is less well-
established. Such limitations are further compounded 
when tracing vaccine antigens in complex physiological 
environments, mimicking those conditions encountered 
in  vivo. Furthermore, the inevitable alterations to 
the physiochemical properties of the antigen and its 
co-adsorbed antigen would likely affect the mechanisms 
by which their cellular uptake subsequently ensues [7, 64, 
89].
Recently, the use of direct-fluorescent labelling has 
allowed for the conformation and intracellular fate 
of a model amyloid-β42 (Aβ42) peptide antigen to be 
followed in a cellular-based model of vaccination 
[163]. Therein, simulated vaccines were prepared 
adjuvanted with lumogallion-labelled ABAs that were 
subsequently co-cultured with THP-1 cells. The longer 
amino acid variant of amyloid, Aβ42, has frequently 
been implemented in the aetiology of Alzheimer’s 
disease, depositing in brain tissue as extracellular senile 
plaques, in a β-sheet rich conformation [171–173]. These 
aberrant misfolded deposits are suggested to break 
down into neurotoxic oligomeric Aβ species, triggering 
a progressive cascade of deleterious effects [171]. 
Thioflavin T (ThT) binds to mature amyloid fibrils in a 
β-pleated sheet conformation that thereby allowed for 
the detection and intracellular fate of the antigen to be 
assessed [163].
This new approach to directly label the moiety of 
interest suggests that Aβ42 is endocytosed by THP-1 
cells through micropinocytosis [174] of which its 
co-formulated ABA  (Alhydrogel®, Adju-Phos® or 
 Imject® Alum) is processed via the alternative pathway 
of autophagy into late-stage autolysosomes [163]. The 
ability of Aβ to evade or disrupt lysosomal capture has 
recently been implicated in separate studies in both 
monocytic [175] and neuronal cell lines [168, 174]. The 
amyloidogenic protein alpha (α)-synuclein that forms 
intraneuronal inclusion or Lewy bodies in Parkinson’s 
disease have also been found to disrupt the formation 
of autolysosomes [176]. Therefore, the ability of 
amyloidogenic proteins to evade lysosomal capture may 
explain their intracellular persistence in  vivo [163, 168, 
174–176]. Furthermore, controlled lysosomal rupture has 
been shown to activate the NALP-3 inflammasome and 
hence such mechanistic modes of action may underlie 
the immunogenicity of vaccine components [177, 178]. 
Taken collectively, these studies highlight the importance 
of monitoring the cellular fate of both the antigen and 
adjuvant constituents of a vaccine in understanding the 
resultant immune response in vivo [163]. In conclusion, 
these approaches may greatly benefit current and future 
clinical trials utilising immunotherapy for the eradication 
of neurodegenerative diseases and other complex disease 
states [179].
Conclusion
Human exposure to aluminium is burgeoning [180] 
with significant implications for human health [166, 
181]. ABAs are effective and cheap but are they safe? 
Confirmation of their safety remains to be addressed 
and will only come from further research on their 
biological activities at injection sites and beyond. All 
ABAs currently in use in vaccination and sub-cutaneous 
immunotherapy require further validation of their 
safety, which means that the manufacturer of AAHS 
should release this ABA so that its safety can be verified 
independently. Burgeoning knowledge regarding the 
biological activities of ABAs now dictates that their safety 
should be evaluated independently of their presence in 
vaccine formulations.
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